Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology-Oncology Fellowship, Duke University School of Medicine 2015 - 2018
  • Internal Medicine Residency, University of Maryland School of Medicine 2012 - 2015
  • M.D., Jefferson Medical College of Thomas Jefferson University 2012
• Research
• 

  Selected Grants

  • Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer awarded by Department of Defense 2019 - 2022
  • Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors awarded by Department of Defense 2018 - 2022
  • Phase II Multicenter Study of Durvalumab (MEDI4736) and Olaparib in PlatinumTreated Advanced Triple Negative Breast Cancer ¿ DORA awarded by Duke University 2018 - 2020
  • Determining the clinical efficacy and predictive biomarkers of mirvetuximab soravtansine (IMGN853) in folate receptor alpha (FRA) expressing, chemotherapy refractory triple negative breast cance 2016 - 2019
  • TNBC Study 2017 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases..” Breast Cancer Res Treat 176, no. 2 (July 2019): 321–28. https://doi.org/10.1007/s10549-019-05211-1.
       Full Text  Link to Item
    • Dent, Susan, Chiara Melloni, Josee Ivars, Sarah Sammons, and Gretchen Kimmick. “Cardiotoxicities of Modern Treatments in Breast Cancer..” Curr Treat Options Cardiovasc Med 21, no. 7 (June 15, 2019). https://doi.org/10.1007/s11936-019-0738-z.
       Full Text  Link to Item
    • Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Target Oncol 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.
       Full Text  Link to Item
    • Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Target Oncol 14, no. 1 (February 2019). https://doi.org/10.1007/s11523-018-0614-x.
       Full Text  Link to Item
    • Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype..” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.
       Full Text  Link to Item
    • Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis..” Neuro Oncol 19, no. 10 (October 1, 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.
       Full Text  Link to Item
    • Sammons, Sarah L., Donna L. Topping, and Kimberly L. Blackwell. “HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles..” Curr Cancer Drug Targets 17, no. 7 (2017): 637–49. https://doi.org/10.2174/1568009617666170330120452.
       Full Text  Link to Item
    • Witkiewicz, A. K., A. Dasgupta, S. Sammons, O. Er, M. B. Potoczek, F. Guiles, F. Sotgia, J. R. Brody, E. P. Mitchell, and M. P. Lisanti. “Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.” Cancer Biology and Therapy 10, no. 2 (July 15, 2010): 135–43. https://doi.org/10.4161/cbt.10.2.11983.
       Full Text

  • Book Sections

    • Sammons, S., M. McNamara, A. K. S. Salama, and J. Crawford. “Immune checkpoint inhibition.” In Side Effects of Medical Cancer Therapy: Prevention and Treatment: Second Edition, 315–53, 2018. https://doi.org/10.1007/978-3-319-70253-7_12.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.